Keywords
Biomarkers
Drug safety
Psoriasis
Methotrexate
Single-nucleotide polymorphism
Adverse reactions
Submitted : 2024-04-16
Accepted : 2024-05-01
Published : 2024-05-16
Abstract
Background: Methotrexate is a highly effective systemic treatment for moderate to severe psoriasis, but drug toxicity may limit its use. Recent evidence suggests that it is necessary to take into account the individual characteristics of methotrexate pharmacokinetics, which are determined by the presence of polymorphisms of genes encoding methotrexate carrier proteins, to predict the risk of methotrexate-induced toxicity. Aim: The research aims to assess the associations of ABCB1 rs1045642 (3435C>T) polymorphism with methotrexate safety for patients with moderate and severe psoriasis. Methods: The study included 75 psoriasis patients treated with methotrexate with 21 days of follow-up duration. Data on adverse drug reactions (ADR) were collected using a clinically structured questionnaire, and complete and biochemical blood tests, and urinalysis were performed. The severity of ADR was assessed using visual analog scales and the CTCAE toxicity scale. The severity of gastrointestinal ADR was assessed using the GSRS questionnaire. Genotyping was carried out by real-time PCR. Results: Gastrointestinal toxicity was detected in 38 patients (50.67%). The mean GSRS score was 7.97 ± 9.18. Analysis of differences in the ADR incidence showed the presence of statistically significant differences in the frequency of ADR in the gastrointestinal tract: the toxic effect of methotrexate was more often observed in carriers of the T allele of the ABCB1 rs1045642 polymorphism (3435C>T), (CC: 2 (14.3%), TC: 18 (52.9%), TT: 18 (66.7%), P = 0.006). Binomial regression demonstrated the presence of a statistically significant effect of the rs1045642 single-nucleotide polymorphism of the ABCB1 gene on the incidence of ADR from the gastrointestinal tract (OR = 8.64, P = 0.008). Conclusion: An association of ABCB1 rs1045642 single-nucleotide polymorphism with the safety of methotrexate therapy in patients with moderate and severe psoriasis was revealed. The data obtained can be used to personalize the prescription of methotrexate to psoriasis patients.
References
Psoriasis. Clinical recommendations, 2020, Approved by the All-Russian Public Organization “Russian Society of Dermatovenerologists and Cosmetologists” January 15, 2020, Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.
Parisi R, Iskandar IYK, Kontopantelis E, 2020, National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ, 2020(369): 1–15. http://doi.org/10.1136/bmj.m1590
Lebwohl M, 2005, Clinician’s Paradigm in the Treatment of Psoriasis. J Am Acad Dermatol, 53(1): S59–69. http://doi.org/10.1016/j.jaad.2005.04.031
Chikin VV, Znamenskaya LF, Minaeva AA, 2014, Pathogenic Aspects of Treatment of Psoriatic Patients. Vestnik Dermatologii Ivenerologii, 2014(5): 86–90.
West J, Ogston S, Foerster J, 2016, Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. PLoS One, 11(5): e0153740. http://doi.org/10.1371/journal.pone.0153740
Yazici Y, Sokka T, Kautiainen H, et al., 2005, Long Term Safety of Methotrexate in Routine Clinical Care: Discontinuation is Unusual and Rarely the Result of Laboratory Abnormalities. Ann Rheum Dis, 64(2): 207–211. http://doi.org/10.1136/ard.2004.023408
Bedoui Y, Guillot X, Sélambarom J, et al., 2019, Methotrexate an Old Drug with New Tricks. Int J Mol Sci, 20(20): 5023. http://doi.org/10.3390/ijms20205023
Ray-Jones H, Eyre S, Barton A, et al., 2016, One SNP at a Time: Moving Beyond GWAS in Psoriasis. J Invest Dermatol, 136(3): 567–573. http://doi.org/10.1016/j.jid.2015.11.025
Sutherland A, Power RJ, Rahman P, et al., 2016, Pharmacogenetics and Pharmacogenomics in Psoriasis Treatment: Current Challenges and Future Prospects. Expert Opin Drug Metab Toxicol, 12(8): 923–935. http://doi.org/10.1080/17425255.2016.1194394
Sychjov DA, 2011, Recommendations for the Use of Pharmacogenetic Testing in Clinical. Kachestvennaya Klinicheskaya Praktika, 2011(1): 3–10.
Lima A, Bernardes M, Azevedo R, et al., 2014, SLC19A1, SLC46A1 and SLCO1B1 Polymorphisms as Predictors of Methotrexate-Related Toxicity in Portuguese Rheumatoid Arthritis Patients. Toxicological Sciences, 142(1): 196–209. http://doi.org/10.1093/toxsci/kfu162
Whetstine JR, Gifford AJ, Witt T, et al., 2001, Single Nucleotide Polymorphisms in the Human Reduced Folate Carrier: Characterization of a High-Frequency G/A Variant at Position 80 and Transport Properties of the His(27) and Arg(27) Carriers. Clin Cancer Res, 7(11): 3416–3422.
Marzolini C, Paus E, Buclin T, et al., 2004, Polymorphisms in Human MDR1 (P-Glycoprotein): recent Advances and Clinical Relevance. Clin Pharmacol Ther, 75(1): 13–33. http://doi.org/10.1016/j.clpt.2003.09.012
Hallas J, Harvald B, Gram LF, et al., 1990, Drug Related Hospital Admissions: The Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. J Intern Med, 228(2): 83–90. http://doi.org/10.1111/j.1365-2796.1990.tb00199.x
Stockwell DC, Slonim AD, 2006, Quality and Safety in the Intensive Care Unit. J Intensive Care Med, 21(4): 199–210. http://doi.org/10.1177/0885066606287079
Cvetov VM, 2007, Monitoring of Adverse Reactions of Drugs in an Outpatient Clinic at the Present Stage, dissertation, Chelyabinsk, 130.
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2017, Common Terminology Criteria for Adverse Events (CTCAE) Version 5, viewed January 6, 2022, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Svedlund J, Sjödin I, Dotevall G, 1988, GSRS-A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease. Dig Dis Sci, 33(2): 129–134. http://doi.org/10.1007/BF01535722
Busto U, Naranjo CA, Sellers EM, 1982, Comparison of Two Recently Published Algorithms for Assessing the Probability of Adverse Drug Reactions. Br J Clin Pharmacol, 13(2): 223–227. http://doi.org/10.1111/j.1365-2125.1982.tb01361.x